What is Pfizer's current dividend yield?

As of May 2026, Pfizer pays $1.72 per share annually, yielding approximately 6.5% at the current $26.48 share price. (Source: stockanalysis.com)

What is Pfizer's 2026 revenue guidance?

Management guided for $59.5B–$62.5B in full-year 2026 revenue and $2.80–$3.00 in adjusted EPS, affirmed after Q1 2026 results beat consensus.

How safe is Pfizer's dividend?

Pfizer's $1.72 annual dividend is well-covered by its guided adjusted EPS of $2.80–$3.00. A near-term cut looks unlikely barring a severe pipeline setback.

What happened to Pfizer's COVID revenue?

COMIRNATY and PAXLOVID revenues have normalized significantly from pandemic peaks. Pfizer is actively diversifying into oncology, rare disease, and obesity treatments.

Is the Seagen acquisition paying off?

The ~$43B Seagen deal (closed 2023) added PADCEV, TUKYSA, and the ADC platform. An FDA-approved breast cancer treatment with partner Arvinas shows early pipeline progress.

What is Pfizer's biggest patent cliff risk?

Eliquis (apixaban) faces patent expiration in 2026, exposing billions in annual revenue to generic competition. Management has not fully disclosed replacement revenues at the same scale.

How does Pfizer compare to Eli Lilly on obesity drugs?

Pfizer is developing oral GLP-1 candidates (danuglipron and others) but remains a significant laggard behind Novo Nordisk and Eli Lilly. A clinical win here would be a major upside catalyst.

Does the IRA affect Pfizer's profitability?

The Inflation Reduction Act's Medicare drug price negotiation provisions create long-term margin headwinds for the entire pharma sector, including Pfizer. The impact is expected to be most pronounced from 2027 onward.

What do analysts think about Pfizer stock in 2026?

The consensus price target is $29.29, implying about 10.6% upside from current levels. Ratings skew toward Hold/Buy depending on pipeline confidence. (Source: stockanalysis.com)

PFE Stock Outlook 2026: Is Pfizer's 6.5% Yield a Gift or ...

Pfizer’s 6.5% dividend yield stands out like a neon sign in a sector where most peers yield 2–3%. The question worth asking seriously: is this a screaming income opportunity, or is the market pricing in a structural deterioration that income-focused investors are choosing to overlook?

At $26.48 (May 2026, per stockanalysis.com), PFE sits about 20% off its 52-week low of $21.97 but still well below its 52-week high of $28.75. That range tells a story of a stock searching for a new identity—post-COVID, post-Seagen integration, and mid-pipeline-transition. This analysis cuts through the noise.

The Business: Four Revenue Pillars, One Transformation Story

Pfizer’s revenue base rests on four segments, each at different stages of maturity:

Oncology — The growth engine. The ~$43 billion Seagen acquisition (completed 2023) brought antibody-drug conjugate (ADC) technology including PADCEV (urothelial cancer) and TUKYSA (HER2+ breast cancer). Pfizer is also partnering with Arvinas on a breast cancer treatment that received FDA approval—a concrete early win from the Seagen-era pipeline buildout.

Vaccines — Stabilizing at a lower level. PREVNAR (pneumococcal vaccine) remains a durable franchise. COMIRNATY (COVID vaccine) revenues have normalized from pandemic peaks, removing the boom-bust overhang that depressed investor confidence.

Internal Medicine — Under pressure. Eliquis (apixaban), co-marketed with Bristol-Myers Squibb, faces patent expiration in 2026, exposing one of Pfizer’s largest revenue streams to generic erosion. VYNDAQEL (tafamidis, rare heart disease) is a brighter spot with relatively longer patent protection.

Antiviral/Other — PAXLOVID (COVID antiviral) remains subject to demand volatility. Management has shifted language around this segment toward longer-term endemic disease positioning.

FY2025 Revenue: $62.6B. TTM (through Q1 2026): $63.3B. Full-year 2026 guidance: $59.5B–$62.5B.

Q1 2026: A Beat That Changed the Tone

Q1 2026 results shifted the conversation. Revenue hit $14.5 billion against a consensus of $13.8 billion—a ~5% beat. Adjusted EPS came in at $0.75 versus the $0.72 estimate. Management reaffirmed the full-year guidance and projected “high single-digit annual revenue increases” through 2033.

That 2033 projection is significant. It signals the company believes the pipeline—particularly oncology and potentially obesity—will more than offset the patent cliff losses from Eliquis and others. The market is skeptical. That skepticism is priced into the current P/E of 20.2x, which sits below the sector median.

The Pipeline: Beyond Seagen

The most consequential near-term pipeline development is Pfizer’s oral GLP-1 obesity candidate. The company is developing danuglipron and other oral agents to compete in the weight-loss drug market dominated by Novo Nordisk’s Ozempic/Wegovy and Eli Lilly’s Mounjaro/Zepbound.

Being third or fourth to market with a GLP-1 drug is extremely difficult. However, an oral formulation could differentiate if efficacy and tolerability hold up in late-stage trials. Success here would likely re-rate Pfizer toward a growth multiple. Failure would confirm the market’s pessimistic view.

Beyond obesity, the late-stage hematology candidates and the blood cancer treatments showing positive phase III data are genuine pipeline assets—not speculative moonshots.

Patent Cliff & IRA: The Two Structural Headwinds

Eliquis patent expiration (2026): This is Pfizer’s most immediate structural challenge. Eliquis generated billions annually in co-promotion revenue. Generic apixaban will erode that base quickly. The question is whether oncology launches can fill the gap on a per-dollar basis within 2–3 years.

IRA Medicare drug price negotiation: The Inflation Reduction Act enables Medicare to negotiate prices for high-spend drugs. While Pfizer’s specific drugs subject to negotiation will evolve, the industry-wide impact on net pricing creates a ceiling on revenue growth that didn’t exist before 2022. The full financial effect will crystallize through 2027–2030.

For a retirement portfolio, these headwinds make PFE a “know what you own” holding rather than a passive set-it-and-forget-it position.

Valuation: Justified Discount or Opportunity?

Metric	Pfizer (PFE)	Sector Median
Price (May 2026)	$26.48	—
P/E (TTM)	20.2x	~25x
Dividend Yield	6.5%	~2.5%
Market Cap	$150.9B	—
52-Week Range	$21.97–$28.75	—
Consensus Target	$29.29	—

The P/E discount to sector peers is real and partially justified by patent cliff concerns and Seagen integration costs (ongoing amortization). But a 6.5% yield supported by $2.80–$3.00 in adjusted EPS guidance creates a meaningful income floor. Dividend coverage is comfortable; a cut would require a major earnings miss.

My read: Pfizer trades at a justified discount, but not a permanent one. The discount compresses if obesity trials succeed or oncology launches exceed Street expectations.

Bull / Base / Bear: 12-Month Price Targets

Scenario	Key Assumptions	12-Month Target	vs. Current
Bull	GLP-1 trial win, oncology blockbuster approval, guidance raised	$35	+32%
Base	Guidance met, pipeline steady progress, Eliquis erosion in-line	$29–30	+10–13%
Bear	Eliquis erosion faster than expected, IRA shock, obesity trial failure	$22	-17%

The base case aligns with analyst consensus ($29.29). The bear case revisits the 52-week low zone—painful for income investors who bought at $26+ hoping for the dividend, then see price erosion wipe out 2–3 years of yield.

Tax Considerations for US Investors

IRA and 401(k) holders: Pfizer’s qualified dividend status means dividends taxed at the preferential 15% or 20% rate in taxable accounts (depending on income bracket). Holding PFE inside a traditional IRA or 401(k) defers this tax but loses the qualified dividend rate advantage—tax-inefficient for a high-yield dividend stock. A Roth IRA is the ideal vehicle if you’re in a position to convert or contribute.

Roth conversion timing: Buying PFE in a Roth and collecting the 6.5% yield tax-free is one of the cleanest use cases for a Roth account. If you’re considering a Roth conversion this year, factor in PFE’s potential capital gain recovery as part of the conversion basis calculation.

Tax-loss harvesting: If PFE moves toward the $22 bear-case range, it’s worth pairing with a position in a pharma ETF (XLV, IHE) to harvest the loss while maintaining sector exposure—just mind the wash-sale rule (30-day window).

Competitor Landscape

For context on where PFE fits in large-cap pharma:

Company	Ticker	P/E	Div. Yield	Key Risk
Pfizer	PFE	20.2x	6.5%	Eliquis cliff, obesity race
Merck	MRK	31.4x	3.0%	Keytruda 2028 LOE
Johnson & Johnson	JNJ	~15x	~3.2%	Talc litigation, Darzalex
Eli Lilly	LLY	~50x+	~0.7%	Valuation, GLP-1 concentration
Bristol-Myers Squibb	BMY	~8x	~5.5%	Multiple patent cliffs

The Verdict

Pfizer is an income investor’s holding that requires active monitoring. The 6.5% yield is real and currently covered by earnings. The pipeline has genuine assets—Seagen’s ADC platform is not hype. But the Eliquis cliff is arriving now, obesity is a contested race, and IRA headwinds are structural, not temporary.

For income-focused investors with a 2–3 year horizon who can stomach volatility, PFE at $26 with a dividend reinvestment plan is a defensible position. For investors seeking capital appreciation, the base-case upside (~10%) doesn’t compensate adequately for the pipeline execution risk.

This analysis is for informational purposes only and does not constitute investment advice. All investment decisions should be made based on your own research and risk tolerance.

Data sourced from stockanalysis.com (May 2026). Price targets are author estimates based on publicly available data.